ChemotherapyFDA-approvedSecond-line
Capecitabine
How it works
Converts into a chemotherapy agent that kills rapidly dividing cancer cells.
Cancer types
Efficacy
In clinical trials, around 24% of patients achieved an objective response, with median progression-free survival of approximately 5 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Capecitabine for Metastatic ER Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-2 | The objective response rate was 25.8%, with 17 partial responses. | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Study Examines Effectiveness of Capecitabine in Triple-Negative Breast Cancer | Breast Cancer | observational | Adjuvant capecitabine did not improve disease-free survival (HR = 0.96; 95% CI 0.52-1.78) or overall survival (HR = 0.70; 95% CI 0.33-1.46) in univariable analyses. | Source → |
| Genetic Testing for Breast Cancer Patients on Capecitabine May Be Cost-Effective | Breast Cancer | phase-3 | The genotyping strategy yielded 1.16 QALYs at a cost of $2,832, compared to $2,677 and 1.15 QALYs for the no-genotyping strategy. | Source → |
| Methylcobalamin May Help Prevent Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | phase-3 | Grade ≥2 hand-foot syndrome occurred in 14.5% of patients in the methylcobalamin group, compared to 29.1% in the placebo group. | Source → |
| Capecitabine plus Temozolomide Therapy for Pancreatic Tumors | Pancreatic Cancer | observational | The objective response rates and disease control rates were 26.7 and 66.7%, respectively. | Source → |
| Lu-DOTATATE with Capecitabine Tested in Advanced Gastroenteropancreatic Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The objective response rate was 33.3% in the experimental arm versus 30.6% in the control arm. | Source → |
| Predicting Capecitabine-Induced Diarrhea in Cancer Patients | Colorectal Cancer | lab-study | The area under curve of the model was 0.907, with a specificity of 100.0% and a sensitivity of 71.4% for predicting diarrhea in colorectal cancer patients. | Source → |
| New Treatment Options for Advanced HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Median overall survival for patients in the tucatinib arm was 21.9 months compared with 17.4 months for patients in the control arm. | Source → |
| Long-Term Outcomes of Pancreatic Cancer Treatment | Pancreatic Cancer | phase-3 | The median overall survival was 31.6 months in patients given GemCap. | Source → |
| Phenytoin Interaction with Capecitabine in Cancer Treatment | Colorectal Cancer | observational | — | Source → |
| Tailoring Cancer Treatment for Triple-Negative Breast Cancer Patients | Breast Cancer | phase-3 | Among immune-hot patients, the 5-year disease-free survival rate was 96.9% in the capecitabine group and 79.4% in the control group. | Source → |
| Neoadjuvant Chemotherapy for Rare Lung Tumors Shows Promise | Lung Cancer | observational | There was a 21% regression in the primary tumor size. | Source → |
| Combining two treatments for hormone receptor positive breast cancer | Breast Cancer | phase-2 | The estimated median progression-free survival for the combination was 17.7 months versus 14.6 months for letrozole alone. | Source → |
| Targeted Cancer Treatment Using Carbohydrate-Based Nanoparticles | Colorectal Cancer | lab-study | — | Source → |
| Rare Case of Ependymoma Shows Long-Term Remission with Combination Chemotherapy | Lung Cancer | observational | The patient remained in remission for approximately 29 months. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.